Welcome to Agalimmune
Agalimmune is a biopharmaceutical company with an innovative anti-cancer immunotherapy technology for the treatment of patients with solid tumours.
Our vision is to harness a universal & natural immune activation to drive a patient-specific anti-tumour response; not only to kill the tumor cells at the site of injection, but also to bring about a long-lasting systemic anti-tumor immune response. Agalimmune's Alphaject technology relies on an interaction between the alpha-Gal glycolipid Alphaject product and its interaction with anti-Gal antibodies, the most common natural antibody in humans.
Agalimmune's lead compound, AGI-134, is a fully-synthetic alpha-Gal glycolipid immunotherapy for solid tumours. AGI-134 recruits the patient’s immune system to target autologous tumour antigens, to attack the patient’s own tumour cells.
In addition to its ongoing efforts to develop cancer treatments, Agalimmune also establishes partnerships and collaborations with leading institutions and companies to research and develop pioneering targeted cancer immunotherapies and cell-based immunotherapeutic products. These internal and external efforts will continue to position Agalimmune at the cutting edge of innovative anti-cancer technologies.